ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.

Koessler, T.; Alsina, M.; Arnold, D.; Ben-Aharon, I.; Collienne, M.; Lutz, M.P.; Neuzillet, C.; Obermannova, R.; Peeters, M.; Sclafani, F.; Smyth, E.; Valle, J.W.; Wagner, A.D.; Wyrwicz, L.; Fontana, E.; Moehler, M.

doi:10.1016/j.esmoop.2022.100392

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.

Details

Download: 35180656_BIB_851DF44B5BE1.pdf (324.20 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0

Serval ID

serval:BIB_851DF44B5BE1

Type

Article: article from journal or magazin.

Publication sub-type

Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.

Collection

Publications

Institution

UNIL/CHUV

Title

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.

Journal

ESMO open

Author(s)

Koessler T., Alsina M., Arnold D., Ben-Aharon I., Collienne M., Lutz M.P., Neuzillet C., Obermannova R., Peeters M., Sclafani F., Smyth E., Valle J.W., Wagner A.D., Wyrwicz L., Fontana E., Moehler M.

ISSN

2059-7029 (Electronic)

ISSN-L

2059-7029

Publication state

Published

Issued date

04/2022

Peer-reviewed

Oui

Volume

Number

Pages

100392

Language

english

Notes

Publication types: Congress ; Journal Article ; Review ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Abstract

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Keywords

Gastrointestinal Neoplasms/drug therapy, Humans, Immunotherapy, Medical Oncology, colorectal cancer, neuroendocrine tumours, oesophagus cancer, pancreatic cancer, stomach cancer

URN

urn:nbn:ch:serval-BIB_851DF44B5BE15

OAI-PMH

oai:serval.unil.ch:BIB_851DF44B5BE1

DOI

10.1016/j.esmoop.2022.100392

Pubmed

35180656

Web of science

000819921700001

Open Access

Yes